Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Novel compositions and methods for delivering inhibitory oligonucleotides to cells in a targeted and efficient manner have been developed. More
Related Reports
Market Research Reports provided by reports.innovaro.com
Dec 2010 - 37 pages - $500
Nov 2010 - 40 pages - $500
Jan 2011 - 34 pages - $500
May 2011 - 15 pages - $250
Jul 2011 - 136 pages - $500
Sep 2011 - 146 pages - $500
Dec 2010 - 55 pages - $500
Feb 2011 - 209 pages - $3,500
May 2011 - 34 pages - $500
Dec 2010 - 22 pages - $500
Your selection
Browse By
- Industry sector
- Bioinformatics
- Combinatorial biology
- Combinatorial chemistry
- Drug research platforms
- Genomics
- High throughput screening
- Proteomics
- Therapeutic target
- Adoptive immunotherapy
- Amyloidosis
- Autoimmune disease (non-specific)
- Chronic fatigue syndrome
- Chronic granulomatous disease
- Chronic immunosuppression
- Gout
- Graft versus host disease
- HIV/AIDS
- Immune disorder (non-specific)
- Immune thrombocytopenic purpura
- Immunomodulation
- Immunostimulation
- Immunosuppression
- Lupus erythematosis
- Myalgic encephalomyelitis
- Myasthenia gravis
- Neoplastic disease
- Organ transplant rejection
- Rheumatoid arthritis
- Servere combined immunodeficency
- Sjogren's syndrome
- Systemic sclerosis
- Transplant rejection
- Xenotransplantation
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us